公开(公告)号：EP2350067A2

公开(公告)日：2011-08-03

申请号：EP09740590.6

申请日：2009-10-14

申请人： Schering Corporation

发明人： PALANI, Anandan ,  BERLIN, Michael, Y. ,  ASLANIAN, Robert, G. ,  VACCARO, Henry, M. ,  CHAN, Tin-Yau ,  XIAO, Dong ,  DEGRADO, Sylvia ,  RAO, Ashwin, U. ,  CHEN, Xiao ,  LEE, Yoon, Joo ,  SOFOLARIDES, Michael, J. ,  SHAO, Ning ,  HUANG, Ying, R. ,  LIU, Zhidan ,  WANG, Li Yuan ,  PU, Haiyan

IPC分类号： C07D417/04 ,  C07D417/14 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D285/135 ,  C07D271/113 ,  C07D491/107 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61P3/10

CPC分类号： C07D285/135 ,  C07D271/113 ,  C07D417/04 ,  C07D417/14 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107

摘要： The present invention relates to novel Pyrrolidine, Piperidine and Piperazine Derivatives, pharmaceutical compositions comprising the Pyrrolidine, Piperidine and Piperazine Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disoder, a metabolic disorder, obesity, an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

公开(公告)号：EP2350048A2

公开(公告)日：2011-08-03

申请号：EP09744830.2

申请日：2009-10-14

申请人： Schering Corporation

发明人： PALANI, Anandan ,  XIAO, Dong ,  ASLANIAN, Robert, G. ,  BERLIN, Michael, Y. ,  RAO, Ashwin, U. ,  CHEN, Xiao ,  LEE, Yoon, Joo ,  DEGRADO, Sylvia ,  SHAO, Ning ,  HUANG, Ying, R. ,  LIU, Zhidan

IPC分类号： C07D401/12 ,  A61K31/4427 ,  A61P7/12

CPC分类号： C07D401/06 ,  C07D213/643 ,  C07D213/81 ,  C07D401/12 ,  C07D417/04

摘要： The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.